Insmed Announces Positive Topline Results From Phase 3 ARISE Study of ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with NTM Lung Disease Caused by MAC

Insmed Announces Positive Topline Results From Phase 3 ARISE Study of ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with NTM Lung Disease Caused by MAC

Published

News published by Insmed presenting data from ARIKAYCE® (amikacin liposome inhalation suspension), administered via the optimized eFlow® Technology nebulizer Lamira®.
 

Read the press release

Back to overview